Home Cart Sign in  
Chemical Structure| 1088715-84-7 Chemical Structure| 1088715-84-7

Structure of LY2510924
CAS No.: 1088715-84-7

Chemical Structure| 1088715-84-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation.

Synonyms: LY2510924

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LY2510924

CAS No. :1088715-84-7
Formula : C62H88N14O10
M.W : 1189.45
SMILES Code : O=C(NCC(N[C@@H](C(N[C@H](C(N)=O)CCCCNC(C)C)=O)CCC1=O)=O)[C@@H](NC([C@@]([H])(CCCNC(N)=N)NC([C@H](CCCCNC(C)C)NC([C@]([H])(CC2=CC=C(O)C=C2)NC([C@H](CC3=CC=CC=C3)N1)=O)=O)=O)=O)CC4=CC5=C(C=C4)C=CC=C5
Synonyms :
LY2510924
MDL No. :MFCD30537218

Safety of LY2510924

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of LY2510924

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MOLM-14 1 µM 150 minutes LY2510924 completely blocked binding of the anti-CXCR4 antibody 12G5 to surface CXCR4 and moderately upregulated cell surface CXCR4 expression. Cancers (Basel). 2020 Jun 30;12(7):1737
MV4-11 1 µM 150 minutes LY2510924 partially reduced binding of the anti-CXCR4 antibody 12G5 to surface CXCR4 in a concentration-dependent fashion and moderately upregulated cell surface CXCR4 expression. Cancers (Basel). 2020 Jun 30;12(7):1737
HEK293AD cells 100 nM 20 minutes To evaluate the effect of LY2510924 on CXCR4 dimerization, results showed that LY2510924 significantly reduced CXCR4 dimerization Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29144-29154

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice MOLM-14/Luc/GFP xenograft model Subcutaneous injection 2.5 mg/kg Once daily for 21 days LY2510924 significantly reduced leukemic burden and induced durable mobilization and differentiation of leukemia cells, enhancing the anti-leukemia effects when combined with quizartinib. Cancers (Basel). 2020 Jun 30;12(7):1737
Japanese anchovy Embryos Microinjection 1, 10, 100, 1.0 × 10^3, 1.0 × 10^4, 1.0 × 10^5 nM Single injection, observed until 48 hours post fertilization Evaluate the effect of LY2510924 on PGC migration. Results showed that LY2510924 at 1 × 10^5 nM concentration did not significantly affect PGC dispersion. Front Physiol. 2024 Feb 2;15:1349119
Female athymic Balb/C nude mice Breast cancer metastasis model Tail vein injection 30 μM Evaluate the effect of LY2510924 on breast cancer metastasis Nat Commun. 2018 Jul 4;9(1):2612

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01439568 Extensive Stage Small Cell Lun... More >>g Carcinoma Less << Phase 2 Completed - United States, Colorado ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States, 80218 United States, Florida For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fort Myers, Florida, United States, 33916 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Orlando, Florida, United States, 32804 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Pensacola, Florida, United States, 32503 United States, Illinois For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chicago, Illinois, United States, 60637 United States, Maryland For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bethesda, Maryland, United States, 20817 United States, Missouri For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Springfield, Missouri, United States, 65804 United States, Nebraska For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Omaha, Nebraska, United States, 68114 United States, Ohio For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Cincinnati, Ohio, United States, 45242 United States, South Carolina For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Greenville, South Carolina, United States, 29605 United States, Tennessee For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chattanooga, Tennessee, United States, 37404 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Memphis, Tennessee, United States, 38120 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nashville, Tennessee, United States, 37203 United States, Texas For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fort Worth, Texas, United States, 76104 United States, Virginia For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Richmond, Virginia, United States, 23230 Less <<
NCT01391130 Metastatic Clear Cell Renal Ce... More >>ll Carcinoma Less << Phase 2 Terminated(Study Terminated du... More >>e to Insufficient Efficacy) Less << - -
NCT02737072 Solid Tumor Phase 1 Terminated - -
NCT02652871 Leukemia Phase 1 Recruiting May 2022 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.84mL

0.17mL

0.08mL

4.20mL

0.84mL

0.42mL

8.41mL

1.68mL

0.84mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories